DOPF
Identifiers
  • 2-[4-(3-fluoropropyl)-2,5-dimethoxyphenyl]ethanamine
PubChem CID
Chemical and physical data
FormulaC14H22FNO2
Molar mass255.333 g·mol−1
3D model (JSmol)
  • COc1cc(CCCF)c(cc1CC(C)N)OC
  • InChI=1S/C14H22FNO2/c1-10(16)7-12-9-13(17-2)11(5-4-6-15)8-14(12)18-3/h8-10H,4-7,16H2,1-3H3
  • Key:UIHSFMYQJAKMHD-UHFFFAOYSA-N

DOPF is a designer drug from the substituted amphetamine family. It was first synthesised by Alexander Shulgin and David Nichols in 1989 but was never published at the time, and was finally disclosed in Daniel Trachsel's review of the field in 2013. It has a binding affinity (Ki) of 9 nM at the serotonin receptor 5-HT2A but is not known to have been tested in humans.[1]

See also

References

  1. Trachsel D, Lehmann D, Enzensperger C (2013). Phenethylamine Von der Struktur zur Funktion [Phenethylamine From structure to function] (in German). Nachtschatten Verlag AG. p. 778-780. ISBN 978-3-03788-700-4.



This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.